Get startedLog in
    Picture of CytoMed Therapeutics logo

    GDTC — CytoMed Therapeutics Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUS/A20-F20-F20-F20-F
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-2.05-3.13-4.13-2.52-4
    Depreciation
    Amortisation
    Non-Cash Items0.3751.230.117-0.4650.383
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-0.3660.1120.202-0.058-0.486
    Change in Accounts Receivable
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-1.71-1.4-3.43-2.71-3.7
    Capital Expenditures-0.582-0.474-0.058-1.49-0.703
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-0.2410-2.772.621.63
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-0.824-0.473-2.831.130.929
    Financing Cash Flow Items1.88-0.125-0.047-0.02-0.021
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities4.170.96910.9-0.0650.209
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash1.63-0.9334.64-1.53-2.6